A randomized controlled multicenter clinical trial of vitamin D2 for prevention of COVID-19

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200067023

Enrollment

Unknown

Registered

2022-12-23

Start date

2022-12-19

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

Test group:vitamin D2

Control group:N/A

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Willing to participate in the clinical study and sign the informed consent; 2. Staff members of Peking University Third Hospital, including the hospital headquarters, Capital International Airport Hospital, North Hospital, Beijing Haidian Hospital, Peking University Third Hospital Yanqing Hospital and Peking University Third Hospital Chongli Hospital; 3. Test negative for COVID-19 antigen and have no symptoms related to COVID-19.

Exclusion criteria

Exclusion criteria: 1. Those with serious underlying diseases; 2. Pregnant and lactating women; 3. Long-term vegetarians; 4. Chronic diarrhea, history of subtotal gastrectomy, biliary obstructive disease and pancreatic disease.

Design outcomes

Primary

Measure	Time frame
The infection rate of the novel coronavirus;Proportion of participants whose symptoms of COVID-19 infection were confirmed by antigen testing for more than 7 days;Changes in 25-hydroxyvitamin D (25(OH)D) concentration;	—

Secondary

Measure	Time frame
The duration of chills, dry cough, nasal congestion, runny nose, sore throat, headache, fatigue, muscle pain, joint pain, shortness of breath, dyspnea, chest tightness, loss of smell and taste sensation, conjunctival congestion, nausea, vomiting, diarrhea, abdominal pain and other symptoms after infection with COVID-19;The duration of a positive to negative antigen test after infection;The proportion of asymptomatic COVID-19 infected persons (those who test positive for the etiology of COVID-19 but have no related clinical manifestations);The proportion of people who are mildly infected with COVID-19;The proportion of people infected with the common form of COVID-19;Proportion of severely infected people with COVID-19;The proportion of patients with severe infection after infection of COVID-19;The proportion of infected people who died after infection with COVID-19;	—

Measure

Time frame

The duration of chills, dry cough, nasal congestion, runny nose, sore throat, headache, fatigue, muscle pain, joint pain, shortness of breath, dyspnea, chest tightness, loss of smell and taste sensation, conjunctival congestion, nausea, vomiting, diarrhea, abdominal pain and other symptoms after infection with COVID-19;The duration of a positive to negative antigen test after infection;The proportion of asymptomatic COVID-19 infected persons (those who test positive for the etiology of COVID-19 but have no related clinical manifestations);The proportion of people who are mildly infected with COVID-19;The proportion of people infected with the common form of COVID-19;Proportion of severely infected people with COVID-19;The proportion of patients with severe infection after infection of COVID-19;The proportion of infected people who died after infection with COVID-19;

—

Countries

China

Contacts

Public ContactChunli Song

Peking University Third Hospital

schl@bjmu.edu.cn+86 139 0100 9038

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026